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Chelation of Cadmium without Increased
Renal Cadmium Deposition
by M. George Cherian*
Cadmium (Cd) is mainly accumulated in liver and kidney bound to metallothionein
(MT) and excreted very slowly from the body. In chronic exposure, Cd is gradually
transported from liver to kidney; the renal toxic effects appear when renal Cd concentra-
tion exceeds the critical concentration. In order to prevent the Cd-induced renal disease,
it is important to control the movement of Cd to the kidney and its renal deposition.
However, the chelation of Cd from liver is difficult because of the high affinity of
intracellular MTforCd. Anumber ofchelating agents containing both carboxyl and thiol
groups were able to mobilize and excrete Cd more easily in a short time (1/2 hr) after Cd
exposure than longer times (24 hr), after MT synthesis. The renal deposition of Cd
increased on BAL (2,3-dimercaptopropanol) treatment a short time (1/2 hr) after Cd
exposure. However, it was observed that if BAL was administered 24 hr after Cd
exposure, it could mobilize Cd from hepatic MT and increase the biliary excretion of Cd
without any increase in renal Cd concentration. Studies using a number of structurally
related thiols (mono-, di- and trithiols) showed that the major structural requirement for
in vivo chelation ofCdfromintracellular MTwere the vicinal thiol groups on an aliphatic
chain, and lipophilicity. BAL was the most effective of all the compounds studied and it
did not mobilize Cd to the kidney, when most of the intracellular Cd was bound to MT.
Furthermore, a delayed treatment with BAL or DTPA (diethylenetriamine pentaacetic
acid) after synthesis of MT resulted in an increase in fecal or urinary excretion of Cd in
ratmodelexperiment. Theinjection ofDTPAincombination withBALwasmore effective
in decreasing the concentration of Cd and MT in liver and kidney from rats chronically
exposed to Cd than injection of BAL alone. Since DTPA cannot enter the cell, it may be
acting extracellularly in removing the Cd. The results of these studies suggest that the
specific intracellular binding ofCd to MT is an important factor in protecing kidney, the
critical organ, in the effective chelation ofCd by BAL.
The development ofan effective chelation ther-
apy for cadmium (Cd) hasbeenextremely difficult
because of the special features in the pharmaco-
kinetics and toxicity of Cd compounds. Unlike
other metals, Cd has an unusually longbiological
half-time in human and is excreted very slowly
from the body (1). After absorption from the re-
spiratory and gastrointestinal tracts, Cd is
mainly accumulated in liver and kidney bound to
metallothionein (MT), a low molecular weight
sulfur-rich intracellular protein (2,3). The low
excretion of Cd from the body may be closely
related to its specific intracellular binding to MT.
Although acute and chronic Cd poisonings in hu-
mans are not common, there are isolated cases of
chronic Cd poisoning in workmen and people liv-
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ing in certain polluted areas (4-7). However,
there are no specific biological indicators for
either Cd exposure ortoxicity. In Cd-exposed peo-
ple, the chronic toxicity such as renal dysfunction
will appear only after a long lag period ofseveral
years, and when a critical concentration ofrenal
Cd is reached (8,9). It is known that there is a
gradual mobilization of Cd from liver to kidney
andthe majorcritical organ inchronic Cdtoxicity
is the kidney (10-12). Therefore, it is important
to consider all the factors involved in the renal
deposition ofCd to develop an effective chelation
therapy for Cd and to prevent the Cd induced
renal disease. In this report, some ofthe research
work on the biliary excretion and chelation ofCd
in experimental animals from our laboratory will
be summarized.
Our approach has been to study the normal
excretory pathways of cadmium and to developM. G. CHERIAN
methods to increase the biliary excretion of Cd.
Thus the hepatic Cd could be removed before it
reaches kidney, the critical organ in chronic cad-
mium toxicity. Tb achieve these goals, we have
made use ofvarious chelating agents, containing
bothcarboxyl andthiol groups. Anumber ofstud-
ies were undertaken on chelation therapy for
cadmium, soon after the second world war. Most
of these studies were acute Cd exposure experi-
ments and were carried out by Gilman and co-
workers in the U.S.A. (13), Friberg's group in
Sweden (14) and Eybl's group in Czechoslovakia
(15). All of these studies concluded that it is
difficult to mobilize Cd without acute renal dam-
age. Therefore, chelation ofCd was considered to
be contraindicated. However, little was known
two decades ago about either the excretory path-
ways ofCd or the specific intracellular binding of
Cd to MT (16). The induced synthesis of MT
within a few hours after exposure to Cd has a
marked effect on the pharmacokinetics and toxic-
ity ofCd (3). Since most ofthe Cd becomes intra-
cellular soon after its absorption and is specifi-
cally bound to MT in several organs within a few
hours after exposure, these important factors
should be considered for therapeutic chelation of
Cd. Thus, Cd differs from a number of other
nonessential metals such as lead and mercury in
itstoxicity.
Biliary Excretion of Cd and
Involvement of MT
Previous studies (16,17) from our laboratory
suggested that biliary excretion ofCd may be an
important excretory pathway in a single high
dose exposure. The dose-dependent increase in
biliary excretion of Cd was similar to that of
manganese salts (18) but was different from mer-
cury compounds (19). Although the major intra-
cellular form ofCd is protein bound, the form of
Cd in bile has been partially characterized as a
glutathione conjugate. It is also known that the
induction of MT synthesis by injection ofmetals
can reduce the diffusible form ofCd in the body
and thereby decrease the biliary excretion of Cd
(20,21). Thus, the synthesis ofMT and binding of
Cd to this intracellular protein has a marked
effect on the pharmacokinetics ofCd. Subsequent
studies from other laboratories have confirmed
these results andextendedthem to otherdivalent
metals (22,23). Preinjection ofexperimental ani-
malswithzinc andcoppersalts alsodecreasedthe
biliary excretion of Cd (24) and this effect also
may be due to the induced synthesis of hepatic
MT.
Thus, the biliary excretion of Cd is mainly
regulatedbytwofactors: the intracellular specific
binding ligands such as MT and the level of
exposure. This may be unique to Cdbecause ofits
intracellular localization and specific binding to
MT within a few hours after Cd exposure. Be-
cause ofthe high affinity ofCd for this protein, it
is difficult to mobilize intracellular Cd from MT
and to increase the biliary excretion of Cd with
chelating agents in chronic Cd exposure (24).
Effect of Chelating Agents before
and after MT Synthesis on Biliary
Transport of Cadmium
A systematic study (24) was undertaken in our
laboratory to investigate the effects of various
chelating agents containing carboxyl or/and thiol
groups on mobilization ofCd from rats exposed to
Cd salts. The role ofMT in this process was also
studied. A number of chelating agents such as
2,3-dimercaptopropanol (BAL), DL-penicillamine
and dithioerythritol increased the biliary excre-
tion of Cd within a short time (1/2 hr) after Cd
exposure. All these compounds contained thiol
groups and the dithiol (BAL) was the most effec-
tive ofall the compounds studied. However, these
thiol compounds also increased the deposition of
Cd in the kidney when administered within 30
min of Cd exposure, i.e., before the synthesis of
MT. These results showed little therapeutic value
for mercaptans in acute Cd exposure and were
similar to earlier reports (13,14). Under similar
experimental conditions, chelatingagents suchas
ethylenediaminetetraacetic acid (EDTA) and ni-
trilotriacetic acid (NTA) containing carboxyl
groups were able to increase the urinary excre-
tion of Cd with a small decrease in both hepatic
and renal Cd deposition. Therefore, chelating
agents containing carboxyl groups may be useful
in removing Cd from the body soon after acute
exposures, and these results are in agreement
with previous reports (25-28). Another po-
lyaminopolycarboxylate, diethylenetriaminepen-
taacetic acid (DTPA), and its derivative, Puchel,
also have been found to be effective mobilizing
agents for Cd (29-31). Since most of the carbox-
ylic acid containing complexing agents used in
most ofthese studies are hydrophilic, their action
is limited to the extracellular compartment.
Therefore, they may prevent the cellular uptake
ofCdwhilelipophilic compoundsmayincreaseCd
uptake into the cell soon after exposure of Cd.
Thus, each chelating agent has different effects
on the distribution and excretion of Cd in acute
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Cd exposures before the induced synthesis ofMT
(24,26,27).
Several studies (32-34) have demonstrated
that subcutaneous injection ofmice with precom-
plexed Cd salts with NTA or sodium tripolyphos-
phate (STPP) increased the acute toxicity of Cd,
as measured by mortality. The enhanced acute
toxicity is probably due to the hepatotoxicity of
these complexes of Cd. A similar acute renal
toxicity is reported after injection of Cd com-
plexed with thiol compounds such as cysteine
(35). Complexes of Cd with thiol compounds in-
creased the renal deposition ofCd as compared to
the Cdsalts alone (24). These studies suggestthat
mobilization of Cd, soon after exposure may in-
crease the risk for development of both acute
hepatotoxicity and renal damage. Therefore the
chelating agents should be used with great cau-
tion in acute Cd exposures.
As discussed earlier, the cellular uptake of Cd
is a rapid process and the intracellular Cd re-
mains bound to MT within a few hours after
exposure. MT is a metal sequestering protein and
itcanbindwith 7 g-atoms ofCdvery strongly (log
f3 for Cd = 25.5). The Cd atoms in MT are
tetrahedrally coordinated to cysteinyl residues in
two distinct polynuclear metal clusters, as indi-
cated by 113Cd-NMR studies. Because of this
strong specific intracellular binding, there is lit-
tle excretion of Cd in urine or bile after the
synthesis ofMT. Most ofthe chelating agents that
were effective in mobilization of Cd soon after
exposure showed little effect on Cd excretion or
tissue distribution when administered after the
synthesis of MT (24). The only compound wrhich
increased the biliary and urinary excretion ofCd
after MT synthesis was BAL and it showed a
dose-dependent response. However, the efficiency
of BAL in increasing the excretion of Cd was
sharply reduced with the synthesis ofMT andthe
binding of Cd to MT. Although BAL was less
effective inmobilization ofCdfrom MTthan from
other proteins, the renal level of Cd did not in-
crease when the chelation was started after MT
synthesis (36). Preliminary studies on partial
characterization ofthe biliary form ofCd suggest
the formation of a Cd-BAL complex before the
synthesis ofMT. But the major form ofCd in the
bile when chelated with BAL after MT synthesis
was associated with a 10,000 molecular weight
fraction (24). Further studies suggested that this
was not a simple Cd-BAL complex or Cd-MT, but
may be a polymerized metabolite of BAL or a
ternary complex with MT and similar proteins.
The formation of different types of Cd binding
complexes in vivo in bile after injection of BAL
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FIGURE 1. Chelationofcadmiumwith BALbefore MTsynthe-
sis and the forms of cadmium in bile, blood and tissues.
Cd-P, Cd bound to protein; Cd-AA, Cd bound to ami-
noacids; Cd-Hb, Cd bound to hemoglobin; Cd-BAL, Cd
complexed with BAL; Cd-BAL-M, Cd bound to BAL me-
tabolite.
LIVER BLOOD
Cd - MT Cd -
\+
Cd -
BAL-'-BAL - M(?)
I- BILE_e Cd - BAL - M -
KIDNEY
Hb Cd - MT
MT(?)
BAL - M --Cd - BAL - M
URINE
FIGURE 2. Chelation ofcadmium with BAL after MT synthe-
sis and the forms of cadmium in bile, blood and tissues.
Cd-MT, Cd bound to metallothionein; Cd-Hb, Cdbound to
hemoglobin; BAL-M, metabolites ofBAL; Cd-BAL-M, Cd
bound to metabolites ofBAL.
before and after synthesis ofMT canbe explained
bythepostulatedschemesshown inFigures 1 and
2.
Since Cd has high affinity for amino acids,
peptides andothermacromolecules, no ionic Cd is
found either in the cells or biological fluids. As
shown in Figure 1, before the synthesis ofMT, Cd
is bound nonspecifically to proteins (Cd-P) or
forms diffusible complexes with amino acids (Cd-
AA) in both liver and kidney. In the blood, Cd is
boundto hemoglobin (Cd-Hb) or amino acids (Cd-
AA). IfBAL is injected at this stage, it may only
bepartly converted into its metabolites (BAL-M).
A major portion of this compound may remain
intact anddirectlyform aCd-BALcomplexwhich
canbedetectedinbothurineandbile. Ourresults
suggestthe excretionofCd-BALcomplex inbile if
BAL is injected to Cd-exposed rats before the
synthesis ofMT (36). A part ofthe Cd-BAL com-
plex will also be transported to kidney. This may
result in increased accumulation of Cd in the
kidney.
Ifthe BAL treatment is delayed until the syn-
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entering the cell and reaching the site ofdeposi-
tion ofcadmium.
These studies showthat MTplays an important
role in the specific binding of intracellular Cd,
and in protection of the kidney during chelation
of hepatic Cd by BAL. These conclusions are
contrary to a recent report (39), which claims to
demonstrate that MT plays a minimal role in
determining chelator efficacy with respect to Cd.
Failure to demonstrate the effect of MT in that
report is not surprising, as the conclusions are
based on the use ofa single chelator, DTPA. It is
well known that Cd-MT is an exclusively intra-
cellular complex, while the hydrophilic chelator
DTPA cannot enter the cell, andbinds only extra-
cellular Cd as a result. A few minutes after expo-
sure, Cd is present intracellularly, bound to pro-
teins and other ligands. The amount ofdiffusible
Cd isminimal. Successful removal ofCdfollowing
MT synthesis, then, depends on delivery ofchela-
tor to the intracellular location, and successful
competition with MT (log I3 for Cd = 25.5). DTPA
fails to meet the former criterion.
FIGURE 3. Chelating agents.
thesis ofMT, most ofthe intracellular Cd will be
exclusively bound to MT in both liver and kidney
(Fig. 2). Under this condition, most of the BAL
which has entered the liver and kidney will be
metabolized and part of the Cd from MT can be
removed as Cd-BAUM. This complex does not
enter the blood circulation and there is no in-
crease in the renal Cd levels. Because of its high
polarity, this complex is specifically eliminated
through bile canaliculi into the bile and also
filtered into urine without any reabsorption at
the tubules. Thus, chelation ofCd after synthesis
of MT will result in decreased Cd levels in both
liver and kidney.
The mode of action of BAL in increasing the
biliary Cd excretion without any increased renal
deposition of Cd after MT synthesis is not clear.
We believe that it is related to the formation of
different types of Cd complexes with BAL or its
metabolites in the liverbefore and after synthesis
of MT. The dose ofBAL used in the treatment is
also important for effective chelation after MT
synthesis (36,37). Further studies (36) using di-
mercaptosuccinic acid (DMSA) and 2,3-dimer-
capto-1-propanesulfonic acid (DMPS) which are
structurally similar to BAL showed that these
compounds were not effective in mobilizing Cd
bound to MT in the liver. The lack of effect of
these compounds can be explained by theirhydro-
philic property which may prevent them from
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FIGURE 4. Biliary and urinary excretion of Cd following
chelation. Rats were injected intravenously with 1 mg Cd/
kg as 1o9CdCl2 and 24 hr later, the bile duct was cannu-
lated. They were injected intraperitoneally with either
propylene glycol (c-control) or chelating agents, 400 1tmole/
kg. The numbers (1-10) indicate the chelating agents as
shown in Fig. 3. The bile and urine samples were collected
for 3 hr. The results are means ± SD from six rats in each
group.
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Structural Requirement for
Chelation of Cd from MT in Vivo
Since BAL was one ofthe few compounds effec-
tive in mobilizing Cd from MT, we have compared
the ability of several structurally related mono-,
di- and trithiols to mobilize Cd from hepatic MT.
In this study, chelators containing carboxyl
groups (EDTA and DTPA) were also included
(Fig. 3). The details ofthese studies are published
elsewhere (38). All the chelating agents were
administered in equimolar amounts (400 gmole/
kg) as intraperitoneal injections to rats which
were pretreated with CdCl2 (1 mg/kg), 24 hr ear-
lier. The bile and urine samples were collected for
3 hr after injection ofchelating agents.
The results showed (Fig. 4) that all the dithiol
compounds containing adjacentthiol groups could
mobilize Cd from hepatic MT and increase the
biliary excretion of Cd while none of the other
compounds with nonadjacent thiol groups or one
single thiol group was effective. Compounds with
a third carbon substitution, such as the -OH
group in BAL or the -SH group in propanetrithiol
were more effective than 1,2-dimercaptopropane.
However, propanetrithiol was extremely toxic
and may not have any therapeutic value. DMPS
was not effective because of its hydrophilic prop-
erty. BAL also increased the urinary Cd excretion
under these experimental conditions. Both EDTA
and DTPA increased the urinary excretion of Cd
without any effect on the biliary Cd excretion.
These results show that the structural require-
ments for effective chelation ofCdfrom MT in Cd-
exposed rats are the vicinal thiol groups and
lipophilic properties ofthe chelating agents.
Recent studies (40,41) from our laboratory sug-
gest that injection of BAL and/or DTPA to rats
pretreated with CdCl2, at least 24 hr earlier, can
increase the fecal and urinary excretion of Cd
without any increase in renal Cd levels. There
was a marked decrease in the whole-body reten-
tion and hepatic levels of Cd. These studies also
show that the Cd excreted through the bile is not
reabsorbed from the gastrointestinal tract. After
mobilization of Cd, there was a decrease in the
MT levels in both liver and kidney.
Although these results are promising, more
work should be undertaken to develop better and
nontoxic chelating agents to mobilize Cd from the
body without any renal damage in both acute and
chronic exposures. The need for the search of
specific metal mobilizing agents and their pro-
phylactic use in excessive exposure to toxic
metals are discussed in detail in a recent review
article by Aposphian (42).
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